Cytokinetics director sells 1,000 shares at $74.66

A Cytokinetics director sold 1,000 shares under a Rule 10b5-1 plan, leaving a direct holding of 9,184 shares.

Rhea-AI Filing Summary

CYTOKINETICS INC (CYTK) reports that director Robert E. Landry sold 1,000 shares of common stock on September 11, 2026 in a transaction described as a sale in the open market or a private transaction at $74.66 per share. Following this sale, he directly holds 9,184 shares of Cytokinetics common stock. The transaction is affirmed as having been made under a Rule 10b5-1 trading plan, indicating it was executed according to a pre-established arrangement.

Insider Trade Summary 10b5-1

Net Seller: 1,000 shares

Net Sell 1 txn

Insider Landry Robert E

Role Director

Sold 1,000 shs ($75K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,000	$74.66	$75K

Holdings After Transaction: Common Stock — 9,184 shares (Direct)

Key Figures

Shares sold: 1,000 shares Sale price per share: $74.66 per share Shares held after transaction: 9,184 shares +2 more

5 metrics

Shares sold 1,000 shares Common stock sale by director Robert E. Landry on September 11, 2026

Sale price per share $74.66 per share Price for the 1,000 CYTOKINETICS INC shares sold on September 11, 2026

Shares held after transaction 9,184 shares Direct holdings of Robert E. Landry following the reported sale

Number of sell transactions 1 transaction Total reported insider sale events in this Form 4

Net shares sold 1,000 shares Net change in director Robert E. Landry’s holdings from this filing

Key Terms

Rule 10b5-1 trading plan, open market or private transaction

2 terms

Rule 10b5-1 trading plan regulatory

"The transaction is affirmed as having been made under a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open market or private transaction market

"described as a sale in the open market or a private transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CYTK report for Robert E. Landry?

CYTOKINETICS INC reported that director Robert E. Landry sold 1,000 shares of common stock on September 11, 2026 in a sale described as occurring in the open market or a private transaction at $74.66 per share.

How many CYTK shares does Robert E. Landry hold after this sale?

After the reported sale, director Robert E. Landry directly holds 9,184 shares of CYTOKINETICS INC common stock, as stated in the filing.

Was the September 11, 2026 CYTK insider sale under a Rule 10b5-1 plan?

Yes. The filing affirms that the reported transaction by director Robert E. Landry was made under a Rule 10b5-1 trading plan, indicating it followed a pre-arranged trading schedule.

What was the price per share for Robert E. Landry’s CYTK stock sale?

Director Robert E. Landry sold 1,000 shares of CYTOKINETICS INC common stock at a price of $74.66 per share on September 11, 2026.

How many insider sell transactions did CYTK report in this Form 4?

The Form 4 reports one sell transaction for director Robert E. Landry, covering the sale of 1,000 shares of common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/11/2026 - 07:12 PM Accepted by SEC EDGAR 09/11/2026 - 07:12 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Landry Robert E

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94580

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/11/2026		S		1,000	D	$74.66	9,184	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ John O. Faurescu, attorney-in-fact for Mr. Landry	09/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)